Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

European Urology

Volumn 57, Issue 1, 2010, Pages 49-59

  Abrahamsson, Per Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Androgen deprivation therapy; Antineoplastic agents, hormonal; Gonadotrophin releasing hormone agonists; Intermittent androgen deprivation; Prostate cancer; Prostate specific antigen; Quality of life; Survival; Testosterone

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BUSERELIN ACETATE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449523110     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.07.049     Document Type: Review

References (70)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 175 (2007) 1-8
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
4. Collin S.M., Martin R.M., Metcalfe C., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9 (2008) 445-452
5. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
6. Huggins C., Stevens R., and Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
7. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 22 (1971) 703-721
8. Moreau J.P., Delavault P., and Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther 28 (2006) 1485-1508
9. el-Rayes B.F., and Hussain M.H. Hormonal therapy for prostate cancer: past, present and future. Expert Rev Anticancer Ther 2 (2002) 37-47
10. Chengalvala M.V., Pelletier J.C., and Kopf G.S. GnRH agonists and antagonists in cancer therapy. Curr Med Chem Anticancer Agents 3 (2003) 399-410
11. Morote J., Orsola A., Planas J., et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178 (2007) 1290-1295
12. Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., and Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
13. Bhandari M.S., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 (2005) 8212-8218
14. Heidenreich A., Aus G., Bolla M., et al. Guidelines on prostate cancer. European Association of Urology (2007) 1-114
15. Gleave M., Bruchovsky N., Goldenberg S.L., and Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 34 Suppl 3 (1998) 37-41
16. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., and Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
17. Chen A.C., and Petrylak D.P. Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep 6 (2004) 209-215
18. Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 20 (2006) 909-923
19. Tunn U.W. Intermittent endocrine therapy of prostate cancer. Eur Urol 30 Suppl 1 (1996) 22-25 discussion 38-9
20. Wolff J.M., and Tunn U.W. Intermittent androgen blockade in prostate cancer: rationale and clinical experience. Eur Urol 38 (2000) 365-371
21. Kabir S., Mancuso P., and Rashid P. Androgen deprivation therapy-managing side effects. Aust Fam Physician 37 (2008) 641-646
22. Ziada A., Crawford E.D., Schroeder F.H., Gleave M.E., Miller P.D., and Garnick M.B. Advanced prostate cancer: an update. Rev Urol 2 (2000) S35-S39
23. Rashid M.H., and Chaudhary U.B. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9 (2004) 295-301
24. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., and Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 (1995) 839-844 discussion 844-5
25. Higano C.S., Ellis W., Russell K., and Lange P.H. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 (1996) 800-804
26. Oliver R.T., Williams G., Paris A.M., and Blandy J.P. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49 (1997) 79-82
27. Bouchot O., Lenormand L., Karam G., et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 38 (2000) 543-549
28. Bracarda S., Rosi P., De Angelis V., Mearini E., Porena M., and Tomato M. Phase II study of intermittent androgen suppression (IAS) in prostate cancer patients [abstract D5]. Ann Oncol 11 (2000) 31
29. Bruchovsky N., Klotz L., Crook J., et al. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 107 (2006) 389-395
30. Bruchovsky N., Klotz L., Crook J., and Goldenberg S.L. Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109 (2007) 858-867
31. Crook J.M., Szumacher E., Malone S., Huan S., and Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 53 (1999) 530-534
32. Cury F.L., Souhami L., Rajan R., et al. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 842-848
33. de la Taille A., Zerbib M., Conquy S., et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 91 (2003) 18-22
34. Goldenberg S.L., Gleave M.E., Taylor D., and Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: Minimum of 3 years' follow-up. Mol Urol 3 (1999) 287-292
35. Grossfeld G.D., Small E.J., and Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 51 (1998) 137-144
36. Kurek R., Renneberg H., Lübben G., Kienle E., and Tunn U.W. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 Suppl 1 (1999) 27-31
37. Lane T.M., Ansell W., Farrugia D., et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 73 (2004) 117-122
38. Malone S., Perry G., Eapen L., et al. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int J Radiat Oncol Biol Phys 68 (2007) 699-706
39. Malone S., Perry G., Segal R., Dahrouge S., and Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 96 (2005) 514-520
40. Pether M., Goldenberg S.L., Bhagirath K., and Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 10 (2003) 1809-1814
41. Peyromaure M., Delongchamps N.B., Debre B., and Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 65 (2005) 724-729
42. Prapotnich D, Fizazi K, Escudier B, Mombet A, Catalan R, Vallancien G., A 16-year clinical experience with intermittent androgen deprivation for prostate cancer. Oncological results. Paper presented at: 24th Congress of the European Association of Urology; March 17-21, 2009; Stockholm, Sweden.
43. Prapotnich D., Fizazi K., Escudier B., Mombet A., Cathala N., and Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43 (2003) 233-240 discussion 239-40
44. Sato N., Akakura K., Isaka S., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64 (2004) 341-345
45. Sciarra A., Di Chiro C., and Di Silverio F. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol 18 (2000) 392-400
46. Sciarra A., Di Chiro C., Voria G., et al. Intermittent androgen deprivation (IAD) in patients with localized prostate cancer and a biochemical progression after radical prostatectomy. Minerva Urol Nefrol 52 (2000) 1-6
47. Spry N.A., Kristjanson L., Hooton B., et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42 (2006) 1083-1092
48. Strum S.B., Scholz M.C., and McDermed J.E. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 5 (2000) 45-52
49. Youssef E., Tekyi-Mensah S., Hart K., Bolton S., and Forman J. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 26 (2003) e119-e123
50. Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99 (2007) 1056-1065
51. Leibowitz R.L., and Tucker S.J. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 6 (2001) 177-182
52. Albrecht W., Collette L., Fava C., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 44 (2003) 505-511
53. Calais da Silva FE, Goncales F, Santos A, et al. Evaluation of quality of life, side effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous androgen deprivation [abstract 540]. Presented at: 23rd Annual Congress of the European Association of Urology; March 26-29, 2008; Milan, Italy.
54. de Leval J., Boca P., Yousef E., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1 (2002) 163-171
55. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
56. Langenhuijsen JF, Schasfoort EMC, Heathcote P, et al. Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data [abstract 538]. Presented at: 23rd Annual Congress of the European Association of Urology; March 26-29, 2008; Milan, Italy.
57. Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5105]. Presented at: American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL, USA.
58. Schasfoort E, Heathcote P, Lock T, et al. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 2003;169(Suppl 4):abstract 1483.
59. Tunn U.W., Kurek R., Kienle E., et al. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy [abstract 1458]. J Urol (2004) 171
60. Verhagen PCMS, Wissenburg LD, Wildhagen MF, et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer [abstract 541]. Presented at: 23rd Annual Congress of the European Association of Urology; March 26-29, 2008; Milan, Italy.
61. Tunn U., Eckhart O., Kienle E., and Hillger H. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy - first results of a randomised prospective phase-III clinical trial (AUO study AP06/95). Eur Urol Suppl 2 1 (2003) 24
62. Calais da Silva F.E.C., Bono A.V., Whelan P., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 55 (2009) 1269-1277
63. Mottet N., Lucas C., Sene E., Avances C., Maubach L., and Wolff J.M. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?. Urol Int 75 (2005) 204-208
64. Mottet N, Goussard M, Loulidi S, Wolff J. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial. Paper presented at: 24th Congress of the European Association of Urology; March 17-21, 2009; Stockholm, Sweden.
65. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
66. Gleave M., Klotz L., and Taneja S.S. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 27 (2009) 81-86
67. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007:CD005009.
68. American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update. Linthicum, MD: American Urological Association; 2007.
69. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25 (2007) 1596-1605
70. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. February 2008. http://www.nice.org.uk/CGO58. Accessed on 3 July 2008.